Revive
Collaborates
With University of Health Sciences Antigua To
Pioneer Clinical
Research of
Psychedelics
TORONTO,
June 17, 2021 -- InvestorsHub
NewsWire -- Revive Therapeutics
Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF,
Frankfurt: 31R),
a specialty life sciences company focused on the research and
development of therapeutics for medical needs and rare
disorders, is pleased to
announce it has entered into an agreement
with the
University of Health Sciences Antigua ("UHSA")
to
collaborate on utilizing
Revive's
novel
psychedelic-assisted therapies and pioneering
the
clinical
research and development of psychedelics in
Antigua
and
Barbuda.
"We are
excited to partner with UHSA as the relationship
complements and
accelerates our
research
and
commercial goals
with
psychedelics and
advances
our
patented drug delivery technology
to
deliver
psychedelics
in an
oral thin film
patch
and
topical forms in
human
clinical studies to support regulatory approvals
globally," said
Derrick
WelshMichael
Frank,
COOEO
of
Psilocin
Pharma, a division of the Company.Revive.
Dr.
Adedayo
Akande,
President of UHSA commented: "Through our
partnership with Revive Therapeutics, we have the unique
opportunity to become a regional leader in the research of
psychoactive therapies for mental health. Our medical students
will now
have
access to the scientific knowledge and uses
of
treatments long before joining
the
physician workforce, which is a great
benefit. We
too
are excited to
partner
with Revive as we contribute to the future of
medicine."
As part
of the proposed
collaboration, Revive and UHSA aims
to accomplish the following activities:
-
Development of a
Psychedelic treatment center in Antigua and
Barbuda
using Revive's
novel
formulations and delivery forms of psychedelics, including its
proprietary psilocybin oral-thin film product to treat mental
health and substance abuse disorders;
-
Research on UHSA's
campus will exclusively use Revive's
intellectual
property, developed at the
University of Wisconsin-Madison, with the aim to be
the foundation for novel psychedelic therapies
for research and commercial use in Antigua and Barbuda;
-
Conduct
clinical studies to support regulatory drug approvals in the
Caribbean and to accelerate U.S. FDA clinical development plans;
and
-
Establishment of a
Master's in Psychedelic Medicine for Doctor of Medicine
students
and for those seeking to expand their knowledge of the field of
psychedelic medicine.
Founded
in 1982, the University of Health Sciences Antigua
located
in Dow's Hill, Piccadilly Antigua is an outstanding academic
institution dedicated to educating exemplary physicians, nurses,
postgraduates, and researchers in accordance with the highest
professional standards who will integrate
clinical, biomedical and behavioral knowledge to promote the health
and well-being of patients and communities. For more information,
visit
www.UHSA.ag.
About
Revive Therapeutics Ltd.
Revive is
a life sciences company focused on the research and development of
therapeutics for infectious diseases and rare disorders, and it is
prioritizing drug development efforts to take advantage of
several regulatory incentives awarded by the FDA such as Orphan
Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease
designations. Currently, the Company is exploring the use of
Bucillamine for the potential treatment of infectious diseases,
with an initial focus on severe influenza and COVID-19. With its
recent acquisition of Psilocin Pharma Corp., Revive is advancing
the development of Psilocybin-based therapeutics in various
diseases and disorders. Revive's
cannabinoid
pharmaceutical portfolio focuses on rare inflammatory diseases and
the company was granted FDA orphan drug status designation for the
use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver
disease) and to treat ischemia and reperfusion injury from organ
transplantation. For more information, visit
www.ReviveThera.com.
For more
information, please contact:
Michael
Frank
Chief
Executive Officer
Revive
Therapeutics Ltd.
Tel: 1
888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation
Services Provider has reviewed or accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
This press release contains 'forward-looking information' within
the meaning of applicable Canadian securities legislation. These
statements relate to future events or future performance. The use
of any of the words "could", "intend", "expect", "believe", "will",
"projected", "estimated" and similar expressions and statements
relating to matters that are not historical facts are intended to
identify forward-looking information and are based on
Revive's
current belief or assumptions as to the outcome and timing of such
future events. Forward looking information in this press release
includes information with respect to the
the
Company's cannabinoids, psychedelics and infectious diseases
programs.
Forward-looking information is based on reasonable assumptions that
have been made by Revive at the date of the information and is
subject to known and unknown risks, uncertainties, and other
factors that may cause actual results or events to differ
materially from those anticipated in the forward-looking
information. Given these risks, uncertainties and assumptions, you
should not unduly rely on these forward-looking statements. The
forward-looking information contained in this press release is made
as of the date hereof, and Revive is not obligated to update or
revise any forward-looking information, whether as a result of new
information, future events or
otherwise, except as required by applicable securities laws. The
foregoing statements expressly qualify any forward-looking
information contained herein. Reference is made to the risk factors
disclosed under the heading "Risk Factors" in the Company's annual
MD&A for the fiscal year ended June 30, 2020, which has been
filed on SEDAR and is available under the Company's profile
at www.sedar.com.